TG Therapeutics, Inc. Earnings Recaps
Q2 2026
Aug 5, 2026
Shares dropped 6.3% following the quarter as investors reacted negatively to a cautious outlook and the implied challenges expanding beyond the core BRIUMVI IV franchise, despite steady commercial execution and pipeline progress.
Key takeaways
- BRIUMVI sales continued to grow, approaching a $1 billion annualized run rate with expanding physician adoption and new patient starts.
- Positive Phase III ENHANCE data supported a simplified single-infusion initiation, potentially easing patient and provider burden by mid-2027.
- Subcutaneous BRIUMVI showed promising Phase I bioavailability data; Phase III results are expected late this year or early next, with the subcutaneous formulation poised to roughly double the addressable market.
- Early-stage expansion efforts include Phase I in myasthenia gravis and Phase II initiation in treatment-resistant schizophrenia, though these remain speculative and modest investments.
- The cautious tone around broader franchise growth, timing uncertainties around subcutaneous data, and exploratory pipeline projects likely tempered enthusiasm, contributing to the stock’s material decline.
Q3 2025
Nov 5, 2025
TG Therapeutics reported robust Q3 2025 results, highlighted by impressive sales growth for BRIUMVI, which continues to outperform market expectations. The company remains committed to innovation and disciplined financial management.
Key takeaways
- BRIUMVI generated approximately $153 million in U.S. net sales for Q3, exceeding internal targets and market forecasts.
- Enrollment in pivotal studies for a simplified dosing schedule and subcutaneous ublituximab is progressing well, with potential launches anticipated in 2027 and 2028, respectively.
- The recently completed $100 million share repurchase program and an additional authorized program reflect TG's commitment to returning capital to shareholders.
- Continued strong demand and physician engagement for BRIUMVI highlight the growing preference for anti-CD20 therapies in MS treatment.
- Intermediate data reveals significant efficacy and safety of BRIUMVI, with 90% of patients remaining free from disability progression after six years of treatment.